Improved method for differentiation of stem cells in vivo by administration of morphogens with mesoporous silica and corresponding pharmaceutical active ingredients

摘要

Administration system for the administration of a pharmaceutical active principle in mammals, the pharmaceutical active principle comprising a set composed of stem cells and mesoporous silica containing a releasable agent, in which said porous silica has a surface area greater than 200 m2 / g a pore size of between 1.5-50 nm, and, wherein the porous silica particles have a particle shape comprising spheres or rod-shaped particles, wherein the releasable agent is selected from the group consisting in fibroblast growth factors (FGF), Wnt, members of the transforming growth factor (TGF) -beta family, Hedgehog proteins (hh), retinoic acid, vascular endothelial growth factor (VEGF), Dickkopf (Dkk) - 1, insulin, activin, SDF-1 / CXCL12, pleiotrophin (PTN), insulin-like growth factor 2 (IGF2), ephrin B1 (EFNB1), cAMP, semaphorins, slits, netrins, NCAM, L1-CAM, NGF , BDNF, NT3, NT4 / 5, GDNF , artemine, persephin, CNTF, LIF, oncostatin M, cardiotrophin 1, CDNF / MANF, wherein said releasable agent is 1-60% of the total weight of the active pharmaceutical ingredient, for use in the controlled administration of the releasable agent for control stem cell differentiation after transplantation of stem cells co-implanted with mesoporous silica, for the treatment of Parkinson's disease or amyotrophic lateral sclerosis or spinal muscular atrophy or stroke or head injury or spinal cord injury.